Clinical and anti-inflammatory effects of ultra-short preseasonal vaccine to Parietaria in asthma
- 19 February 2013
- journal article
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 7 (4) , 207-215
Abstract
Objective: The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of immunotherapy contributes to asthma control. Methods: Four subcutaneous injections of the active product (Pollinex Quattro) were administered, before the pollen season, to 20 Parietaria-sensitive mild, untreated asthmatics (M/F: 12/8; age: 38 ± 14 years). After the screening visit (visit 1), asthma control was assessed by the Asthma Control Test (ACT) immediately before the first (visit 2) and immediately after the last (visit 5) injections, as well as during the pollen season (visit 6). Bronchial and alveolar exhaled nitric oxide (NO) concentrations were also measured. Nine Parietaria-sensitive mild asthmatics (M/F: 3/6; age: 40 ± 12 years) served as untreated controls. Results: The ACT remained constant during allergen exposure in specific immunotherapy (SIT)-treated asthmatics (visit 2: 22 ± 3.2; visit 5: 23 ± 2.8; visit 6: 22 ± 3.6; analysis of variance [ANOVA], p = 0.47), whereas it dropped during pollen exposure in controls (visit 2: 20 ± 2.5; visit 5: 21 ± 2.8; visit 6: 16 ± 5.7; ANOVA, p = 0.01). The forced expiratory NO (FENO) values significantly increased during pollen exposure in both groups; however, the alveolar NO concentrations remained stable in SIT-treated asthmatics (p = 0.11), whereas they doubled in controls (p = 0.01). Conclusions: The current findings show that the preseasonal vaccine adjuvated with MPL contributes to the maintenance of control of asthma during the pollen season.Keywords
This publication has 29 references indexed in Scilit:
- Safety, tolerability, and impact on allergic inflammation of autologous E.coli autovaccine in the treatment of house dust mite asthma - a prospective open clinical trialBMC Complementary and Alternative Medicine, 2011
- Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollenAllergy and Asthma Proceedings, 2011
- Anti-inflammatory effects of pre-seasonal Th1-adjuvant vaccine to Parietaria judaica in asthmaticsJournal of Asthma and Allergy, 2011
- Peripheral airway/alveolar nitric oxide concentration in asthmaThorax, 2010
- Exhaled Nitric Oxide and Exhaled Breath Condensate pH in Severe Refractory AsthmaChest, 2010
- Clinical patterns in asthma based on proximal and distal airway nitric oxide categoriesRespiratory Research, 2010
- Fractional exhaled nitric oxide in asthma: an updateRespirology, 2009
- Exhaled nitric oxide predicts control in patients with difficult-to-treat asthmaEuropean Respiratory Journal, 2009
- Alveolar nitric oxideversusmeasures of peripheral airway dysfunction in severe asthmaEuropean Respiratory Journal, 2006
- Allergen Immunotherapy: Therapeutic Vaccines for Allergic DiseasesAnnals of Allergy, Asthma & Immunology, 1998